Published 1 day ago • loading... • Updated 13 hours ago

Sanofi Raises Sales Outlook on Dupixent Strength in Boost for New CEO

On Thursday, Sanofi raised its full-year sales growth forecast to 10% at constant exchange rates, driven by strong demand for blockbuster asthma drug Dupixent.
Second-Quarter revenue reached €11.6 billion, a 16% increase, while business operating income hit €3.29 billion, surpassing the €2.96 billion average estimate from Vara Research.
CEO Belen Garijo confirmed Sanofi is abandoning three R&D programs, including amlitelimab and itepekimab, as part of an accelerated transformation roadmap to prioritize pipeline improvements.
Garijo projects Dupixent sales will reach around €25 billion by 2030, with newer launch products expected to add approximately €10 billion to future revenues.
Sanofi decided to stop development on COPD treatments after "changes in the competitive landscape," citing interim results that "did not meet the internal efficacy expectations on clinical endpoints.

Insights by Ground AI

14 Articles

At Sanofi, the New Boss Is Keeping Track of Immunology and Vaccines, but Is Reviewing the Method in Depth

Belén Garijo has been managing the French pharmaceutical group for less than three months and wants to tighten the strategy of the French pharmaceutical laboratory around research and development.

13 hours ago·Paris, France

Read Full Article

Reuters

+3 Reposted by 3 other sources

Center

Sanofi drug pipeline worries, Dupixent dependence shake shares

Sanofi raised its full-year sales forecast on Thursday on strong demand for blockbuster ‌drug Dupixent, but its shares fell 8% as investors focused on pipeline cuts and one-off gains.

14 hours ago·London, United Kingdom

Read Full Article

Le Figaro

Lean Right

Discipline, Innovation and Acquisitions: Belén Garijo Unveils His Potion to Boost Sanofi's Growth

DECRYPTAGE - Executive Director of the French pharmacy giant for three months, she raised her ambitions for 2030.

14 hours ago·Paris, France

Read Full Article

Pharmaphorum

Center

Sanofi drops two more programmes in R&D clear-out

Shortly after terminating one late-stage R&D programme, Sanofi confirmed in its second-quarter update that two others are being scrapped.

18 hours ago

Read Full Article

Globo

Lean Right

Profit of Sanofi Falls 91.3% in the 2nd Quarter, to 343 Million Euros

Sanofi raised its estimates for the full year, citing a strong performance in the first half of the year, at the time when its new executive president stated that she was working on a plan to reformulate the portfolio of medicines in development of French pharmaceuticals. Exclusive material for subscribers. To have full access, access the link of the subject and register.

21 hours ago·Rio de Janeiro, Brazil

Read Full Article

endpoints.news

Garijo's plan to revamp Sanofi: an R&D cleanup, more M&A and a China push

Three months into her role as CEO at Sanofi, Belén Garijo gave some insight on how she plans to boost the French company’s mid- to long-term growth in the face of a looming patent cliff ...

16 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year